The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA

The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA

Abstract Enhanced expression of anti-apoptotic B-cell lymphoma 2 (BCL-2) protein is frequent in cancer. Targeting of BCL-2 with the specific inhibitor ABT-199 (Venetoclax) has significant clinical activity in malignant diseases such as chronic lymphocytic leukemia and multiple myeloma. The small mol...

Full description

Bibliographic Details
Main Authors: Sandra Weller, Astrid Toennießen, Benjamin Schaefer, Tobias Beigl, Alina Muenchow, Kathrin Böpple, Ute Hofmann, Bernhard F. Gillissen, Walter E. Aulitzky, Hans-Georg Kopp, Frank Essmann
Format: Article
Language:English
Published: Nature Publishing Group 2022-04-01
Series:Cell Death Discovery
Online Access:https://doi.org/10.1038/s41420-022-01009-1

Internet

https://doi.org/10.1038/s41420-022-01009-1

Similar Items